GetTopicDetailResponse(id=16d46803077, topicName=特羅凱, introduction=特羅凱, content=null, image=null, comments=4, allHits=1186, url=https://h5.medsci.cn/topic?id=68030, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=5037, tagList=[TagDto(tagId=5037, tagName=特羅凱)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1984111, encodeId=793e1984111ee, content=<a href='/topic/show?id=16d46803077' target=_blank style='color:#2F92EE;'>#特羅凱#</a>, objectTitle=年老體弱的肺癌患者，特羅凱用多大劑量合適？, objectType=article, longId=195720, objectId=57ab195e2094, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57ab195e2094, replyNumber=0, likeNumber=93, createdTime=2021-05-02, rootId=0, userName=qblt, userId=640c454, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57ab195e2094, moduleTitle=年老體弱的肺癌患者，特羅凱用多大劑量合適？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=57ab195e2094)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984110, encodeId=79551984110aa, content=<a href='/topic/show?id=16d46803077' target=_blank style='color:#2F92EE;'>#特羅凱#</a>, objectTitle=難治性肺鱗狀細(xì)胞癌患者接受阿法替尼治療后的生存期優(yōu)于特羅凱, objectType=article, longId=56751, objectId=154056e51aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=154056e51aa, replyNumber=0, likeNumber=60, createdTime=2015-12-17, rootId=0, userName=qblt, userId=640c454, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=154056e51aa, moduleTitle=難治性肺鱗狀細(xì)胞癌患者接受阿法替尼治療后的生存期優(yōu)于特羅凱, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=154056e51aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984109, encodeId=70f81984109ef, content=<a href='/topic/show?id=16d46803077' target=_blank style='color:#2F92EE;'>#特羅凱#</a>, objectTitle=特羅凱、易瑞沙、凱美納三藥比較, objectType=article, longId=39752, objectId=473f39e52a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=473f39e52a9, replyNumber=0, likeNumber=69, createdTime=2015-02-15, rootId=0, userName=qblt, userId=640c454, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=473f39e52a9, moduleTitle=特羅凱、易瑞沙、凱美納三藥比較, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=473f39e52a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984108, encodeId=5120198410836, content=<a href='/topic/show?id=16d46803077' target=_blank style='color:#2F92EE;'>#特羅凱#</a>, objectTitle=ASCO2013年會：EGFR野生的NSCLC人群中泰索帝療效優(yōu)于特羅凱, objectType=article, longId=18976, objectId=8b94189e681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b94189e681, replyNumber=0, likeNumber=0, createdTime=2014-03-27, rootId=0, userName=qblt, userId=640c454, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b94189e681, moduleTitle=ASCO2013年會：EGFR野生的NSCLC人群中泰索帝療效優(yōu)于特羅凱, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8b94189e681)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
